source
- Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent winA Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…
- AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trialA Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in…